BioRestorative Therapies
-
Biologics
BioRestorative Therapies Reports Positive Preliminary Phase 2 BRTX-100 Clinical Data
– Blinded preliminary data demonstrate a positive trend and clear signal in Primary and Secondary endpoints – – Patient reported…
Read More » -
Biologics
BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health
– Allows for the processing of allogeneic (non-autologous) donor tissue material, including stem cells, for medical research – MELVILLE, N.Y.,…
Read More » -
Financial
BioRestorative Therapies Reports Second Quarter 2024 Financial Results and Provides Business Update
MELVILLE, N.Y., Aug. 13, 2024 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator…
Read More » -
Financial
BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results
– Significant YoY improvement in operating performance – – Ends Q1-2024 with $16.4 million cash, cash equivalents, and marketable securities –…
Read More » -
Regulatory
BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment
— Amendment replaces saline injections with sham injections in the control group — MELVILLE, N.Y., April 16, 2024 (GLOBE NEWSWIRE)…
Read More » -
Spine
BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease
— Collaboration follows recent manufacturing/clinical process enhancements that have tripled monthly trial capacity — — Patient enrollment expected to be…
Read More » -
Financial
BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K
MELVILLE, N.Y., April 01, 2024 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused…
Read More » -
Financial
BioRestorative Therapies Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $8.1 Million Gross Proceeds Priced At-the-Market
MELVILEE, N.Y., Feb. 06, 2024 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (“BioRestorative” or the “Company”) (NASDAQ: BRTX), a clinical stage…
Read More » -
Spine
BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease
— Preliminary data includes 26 and 52-week follow-up end points as part of ongoing Phase 2 trial — — Company…
Read More » -
Biologics
BioRestorative Therapies to Present Preliminary BRTX-100 Clinical Data at the Orthopaedic Research Society (ORS) 2024 Annual Meeting
— Blinded data from the ongoing Phase 2 clinical trial of BRTX-100 to be described in poster presentation — —…
Read More » -
Biologics
BioRestorative Therapies Announces Activation of Northwell Health in the Company’s Phase 2 Clinical Trial Targeting Chronic Lumbar Disc Disease
–Site activation allows for patients in the State of New York to participate in the BRTX-100 trial— –15 Clinical Sites Identified, 12…
Read More » -
Biologics
BioRestorative Therapies Announces $2.1 Million Registered Direct Offering
MELVILLE, N.Y., July 11, 2023 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical stage…
Read More » -
Biologics
BioRestorative Therapies Announces Key Milestone of Dosing Completion in Safety Cohort of Phase 2 Trial Targeting Chronic Lumbar Disc Disease
—Clinical data expected to be reviewed by independent data safety monitoring board (DSMB) as to initial safety dosing profile of BRTX-100– MELVILLE,…
Read More » -
Biologics
BioRestorative Therapies Receives License from New York State Department of Health to act as Tissue Bank for Mesenchymal Stem Cell Processing
–License will enable expanded clinical operations for investigator-initiated trials and potential “right to try” uses of BRTX-100.— MELVILLE, N.Y., May 31,…
Read More » -
Biologics
BioRestorative Therapies Enters Agreement with Regenexx, Granting BRTX Exclusive License Rights for Intellectual Property Related to the Development and Commercialization of its BRTX-100® Disc Program to Treat Chronic Lumbar Disc Disease
— Intellectual Property Provides a Cell-Based Therapeutic Platform Designed to Target All Avascular Zones— MELVILLE, N.Y., Dec. 05, 2022 (GLOBE NEWSWIRE)…
Read More »